Sponsors (26)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Creates a federal right for individuals to obtain FDA-approved medicines and for health care providers to prescribe, provide information about, and facilitate access to those medicines without being blocked by state or federal rules. It bars laws, rules, or practices that single out or restrict access to FDA-approved medicines, lets the U.S. Attorney General and private parties sue to stop unlawful restrictions, and requires courts to award injunctions and fees to prevailing plaintiffs. Applies nationwide to federal, state, and local laws and their enforcement, treats government enforcers as subject to suit, requires courts to construe the law broadly to expand access, and takes effect immediately on enactment.
The bill expands and enforces a nationwide right to obtain and prescribe FDA‑approved medicines—improving patient access and reducing provider uncertainty—while significantly limiting state and local regulatory authority and raising the prospect of increased litigation costs and legal conflicts.
Patients (including people with chronic conditions, Medicaid and Medicare beneficiaries, and uninsured individuals) gain a clear, enforceable federal right to obtain FDA-approved medicines, expanding practical access to approved treatments nationwide.
Health care providers (doctors, nurses, pharmacists, hospitals and health systems) receive clearer federal protections to prescribe, discuss, refer for, and provide FDA-approved medicines, reducing legal ambiguity about clinical practice.
Providers, pharmacies, and multi-state health systems benefit from a uniform nationwide rule that reduces cross-state legal uncertainty for supplying FDA-approved medicines.
State and local governments (and their public-health authorities) would lose or see constrained authority to impose targeted safety, licensing, zoning, or distribution restrictions on medicines, reducing local regulatory flexibility to manage public-health risks.
The Act significantly increases the likelihood of litigation (private suits, federal enforcement, and fee-shifting), producing higher legal costs and administrative burdens for states, localities, hospitals, and taxpayers.
Broad prohibitions against measures that 'impede access' or 'single out' FDA-approved medicines could undermine narrowly tailored public-health or safety rules (e.g., facility or distribution standards) if courts interpret protections expansively.
Introduced July 17, 2025 by Deborah K. Ross · Last progress July 17, 2025